Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.

Zacks Investment Research • Sep 9, 2026

Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Do Options Traders Know Something About DaVita Stock We Don't?

Investors need to pay close attention to DVA stock based on the movements in the options market lately.

Zacks Investment Research • Sep 3, 2026

4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds

An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.

Zacks Investment Research • Aug 28, 2026

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

In fact, it's a healthcare company. It is a strong player in its chosen niche.

The Motley Fool • Aug 27, 2026

Alebund Pharmaceuticals Announces 2026 Interim Results

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

PRNewsWire • Aug 26, 2026

DVA & Humana Expand Value-Based Care for Kidney Disease Patients

DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.

Zacks Investment Research • Aug 26, 2026

DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease

More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.

PRNewsWire • Aug 25, 2026

Is DaVita (DVA) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Aug 6, 2026

DaVita Q2 Earnings Call Highlights

DaVita NYSE: DVA reported second-quarter results that management said were broadly in line with expectations, supported by accelerating treatment-volume growth and lower mortality among patients. The kidney-care company reaffirmed its full-year 2026 guidance, while outlining plans to expand access to newer dialysis technology designed to improve clearance of so-called middle molecules.

MarketBeat • Aug 5, 2026